导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.91% | 4157/4773 |
| 近一周 | -2.32% | 3724/5465 |
| 近一月 | -0.07% | 719/5421 |
| 近一季 | -9.26% | 3531/5231 |
| 近半年 | -18.48% | 4302/4920 |
| 近一年 | -2.27% | 3031/4394 |
| 近两年 | 44.28% | 1711/2954 |
| 近三年 | 14.68% | 1648/2253 |
| 成立以来 | 64.09% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.96% 3731/4961 |
-1.43% 3350/5312 |
- - |
- - |
| 2025 | 32.41% 1186/4813 |
-1.59% 2702/3635 |
11.96% 121/4076 |
7.55% 3444/4524 |
11.74% 156/4813 |
| 2024 | 9.42% 1471/3463 |
-6.01% 1991/2808 |
-2.12% 1140/3014 |
13.05% 2255/3129 |
5.21% 624/3463 |
| 2023 | -9.09% 1105/2656 |
1.38% 1579/2280 |
3.65% 93/2385 |
-10.09% 1948/2515 |
-3.78% 786/2655 |
| 2022 | -25.52% 1324/2207 |
-22.30% 1693/1919 |
3.58% 1129/2016 |
-7.25% 118/2113 |
-0.23% 1580/2208 |
| 2021 | 25.08% 114/1822 |
-17.26% 1196/1255 |
14.53% 251/1330 |
11.07% 115/1466 |
18.83% 32/1822 |
| 2020 | 77.34% 49/1250 |
-0.70% 190/1028 |
12.56% 683/1067 |
30.86% 8/1164 |
21.24% 55/1184 |
| 2019 | 25.39% 601/1092 |
33.01% 151/754 |
-8.67% 602/804 |
4.10% 217/850 |
-0.84% 891/918 |
| 2018 | -28.34% 439/834 |
- - |
- - |
- - |
-13.51% 537/691 |
| 2017 | -12.27% 551/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝中证军工ETF VS. 长安沪深300非周期A(740101) |